Researchers at the University of South Florida have developed a new chemotherapeutic for the treatment of ovarian cancer using the compound zeta-stat.
Ovarian cancer is known to be the most lethal type of gynecological cancer with an average diagnostic stage of stage III. High fatality rates can be contributed to the fact that there is no efficient screening process. The most common type of ovarian cancer is epithelial ovarian carcinoma, which represents 85-90% of all diagnoses. An overexpression of atypical PKCs (PKC-zeta and others) have been observed in many malignant epithelial ovarian carcinoma cell lines including a subtype known as clear cell ovarian carcinoma (CCOC). Zeta-stat is an identified inhibitor of atypical PKC-zeta. Therefore, an effective treatment utilizing zeta -stat to target atypical PKC-zeta may be an ideal ovarian cancer therapeutic.
Brochure
